New cancer clinical trial: Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

Published on: July 26, 2018 at 12:00PM
Conditions:   KRAS Gene Mutation;   Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions:   Drug: Atezolizumab;   Drug: Cobimetinib;   Other: Laboratory Biomarker Analysis
Sponsor:   National Cancer Institute (NCI)
Recruiting
https://ift.tt/2K0pWGD